CDNA to Acquire Naveris for $160M; Q1 Revenue +39% to $118M; Raises FY26 Guidance
CareDx announced a definitive agreement to acquire Naveris, a precision oncology diagnostics company, for an upfront cash consideration of $160 million, with up to an additional $100 million based on revenue milestones. This strategic acquisition extends CareDx's precision medicine testing services into specialty oncology, targeting a $4.5 billion market. Concurrently, CareDx reported strong first-quarter 2026 financial results, with revenue increasing 39% year-over-year to $118 million and GAAP net income reaching $3 million. The company also raised its full-year 2026 revenue guidance to $447-$465 million and Adjusted EBITDA guidance to $43-$57 million, and announced the divestment of its Lab Products business for $170 million.
Key Highlights
- Agreed to acquire Naveris for $160M upfront, plus up to $100M in milestones.
- Naveris 2025 unaudited revenue was $34M, projected 30-40% annual growth.
- Divested Lab Products business to Eurobio Scientific for $170M cash.
- Q1 2026 revenue increased 39% YoY to $118M.
- Q1 2026 GAAP net income was $3M, compared to $10M net loss in Q1 2025.
- Q1 2026 Adjusted EBITDA was $19M, up from $5M in Q1 2025.
- Raised FY2026 revenue guidance to $447M-$465M and AEBITDA to $43M-$57M.
- Board authorized a common stock repurchase program of up to $100M.